U.S. FDA Grants Breakthrough Therapy Designation to Tividenofusp Alfa for Hunter Syndrome
Denali Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) as a potential treatment for Hunter syndrome (MPS II).
This recognition builds on prior designations, including Fast Track, Orphan Drug, and Rare Pediatric Disease, which were also granted by the FDA for this investigational therapy.
The Breakthrough Therapy Designation is designed to accelerate the development and regulatory review of treatments for serious or life-threatening conditions. To qualify, preliminary clinical evidence must indicate that the treatment provides a significant improvement over existing therapies on at least one clinically important endpoint.
This designation offers benefits such as enhanced guidance from the FDA, involvement of senior reviewers, and eligibility for rolling and priority reviews of the marketing application.
Hunter syndrome, also known as MPS II, is a rare genetic condition primarily affecting males, with over 2,000 individuals impacted in commercially accessible regions. It is caused by mutations in the iduronate-2-sulfatase (IDS) gene, resulting in a deficiency of the IDS enzyme.
Symptoms typically emerge around the age of two and include physical challenges such as organ dysfunction, joint stiffness, hearing loss, and impaired growth. Additionally, cognitive and behavioural symptoms, along with developmental impairments, are common. The disease is characterised by an accumulation of glycosaminoglycans (GAGs) in lysosomes, which are cellular components responsible for breaking down these materials.
Tividenofusp alfa (DNL310) is an investigational therapy developed using Enzyme Transport Vehicle™ (ETV) technology. This innovative approach facilitates the active transport of the IDS enzyme into the brain and ensures broad delivery throughout the body.
The goal is to address the physical, cognitive, and behavioural symptoms associated with Hunter syndrome. In addition to its recent Breakthrough Therapy Designation, tividenofusp alfa has previously received Fast Track designation from the FDA and a Priority Medicines designation from the European Medicines Agency.
It is important to note that tividenofusp alfa remains an investigational drug. Its safety and efficacy have not yet been fully established, and it has not been approved by any regulatory authority for any use.
